1. Home
  2. SAM vs SRPT Comparison

SAM vs SRPT Comparison

Compare SAM & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Boston Beer Company Inc. (The)

SAM

Boston Beer Company Inc. (The)

N/A

Current Price

$220.88

Market Cap

2.2B

ML Signal

N/A

Logo Sarepta Therapeutics Inc. (DE)

SRPT

Sarepta Therapeutics Inc. (DE)

N/A

Current Price

$16.08

Market Cap

2.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SAM
SRPT
Founded
1984
1980
Country
United States
United States
Employees
N/A
N/A
Industry
Beverages (Production/Distribution)
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.0B
IPO Year
1996
2000

Fundamental Metrics

Financial Performance
Metric
SAM
SRPT
Price
$220.88
$16.08
Analyst Decision
Hold
Hold
Analyst Count
14
24
Target Price
★ $198.85
$21.77
AVG Volume (30 Days)
198.3K
★ 2.2M
Earning Date
10-22-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 95.45
N/A
EPS
N/A
★ 2.78
Revenue
$1,964,994,000.00
★ $2,198,237,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$5.78
Revenue Growth
N/A
★ N/A
52 Week Low
$158.68
$14.68
52 Week High
$264.46
$24.68

Technical Indicators

Market Signals
Indicator
SAM
SRPT
Relative Strength Index (RSI) 67.73 37.20
Support Level $211.47 $15.19
Resistance Level $234.88 $18.26
Average True Range (ATR) 7.87 0.92
MACD 0.08 -0.25
Stochastic Oscillator 68.51 8.92

Price Performance

Historical Comparison
SAM
SRPT

About SAM Boston Beer Company Inc. (The)

Boston Beer is a top player in high-end malt beverages and adjacent categories in the US, with strong positions in craft beer, flavored malt beverages, hard cider, and hard seltzer. The bulk of volume and revenue is concentrated in four brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly. Beverages are produced using a hybrid model leveraging both in-house capacities and third-party breweries through contract arrangements. While the firm is required to use distributors to reach end markets, including retailers and on-premises operators, it also employs 500 internal sales representatives to educate the market about its products. The firm generates almost all sales in the US.

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.

Share on Social Networks: